title: [Multiple-organ pathology in septic shock in patients with hemoblastoses].
abstract: A prospective study of 20 patients with hemoblastosis and septic shock (SS) was carried out by invasive monitoring of the central hemodynamics and oxygen transport, evaluation of biochemical and coagulological parameters, and assessment of the severity of clinical condition by the APACHE II and SOFA scores. Septic shock was effectively treated in 12 patients, 5 of them were discharged from the department (group 1) and 7 died in intensive care wards from various complications (group 2). Eight patients died during the first 2 days from SS resistant to therapy (group 3). Group 2 patients were in need of a longer inotropic support than group 1 patients (5.8 +/- 1.6 vs. 2.7 +/- 0.8 days, p < 0.01). The deficit of bases was more expressed in groups 2 and 3 in comparison with group 1 (-11.3 +/- 3 and -2.7 +/- 9.1 mmol/liter vs. 1.4 +/- 4.4 mmol/liter) and left ventricular stroke index (LVSI) and oxygen delivery were lower. LVSI and base deficit were in linear correlation (rho = 0.4, p < 0.05). XIIa-dependent fibrinolysis was suppressed in all patients, which was more pronounced in group 3 in comparison with groups 1 and 2 (135 +/- 47.4 vs. 103 +/- 27 and 88.3 +/- 42.3). According to SOFA score, the severity of cardiovascular disorders during day 1 of SS was the same in all groups, while starting from day 2 it decreased in patients who survived. Acute respiratory failure was lower in group 1 only on day 1 according to SOFA. More pronounced (according to SOFA) hepatorenal failure was observed in group 2 in comparison with other patients. Organ involvement in hemoblastosis was detected at autopsy in 8 out of 13 cases. Hence, the need in prolonged cardiovascular support of SS patients is associated with development of polyorgan involvement. Fibrinolysis suppression is a frequent early manifestation of hemostasis disorders. Specific neoplastic organ involvement was observed in 61.5% patients with hemoblastosis who died from SS and its complications.
authors.forename: G M
authors.initials: GM
authors.lastname: Galstian
authors.forename: V M
authors.initials: VM
authors.lastname: Gorodetskiĭ
authors.forename: E M
authors.initials: EM
authors.lastname: Shulutko
authors.forename: V M
authors.initials: VM
authors.lastname: Budianskiĭ
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Bulanov
authors.forename: A S
authors.initials: AS
authors.lastname: Dobrodeev
authors.forename: N V
authors.initials: NV
authors.lastname: Prosolov
authors.forename: S A
authors.initials: SA
authors.lastname: Vasil'ev
authors.forename: E B
authors.initials: EB
authors.lastname: Orel
authors.forename: L S
authors.initials: LS
authors.lastname: Biriukova
mesh_terms: D018806:APACHE; D001692:Biological Transport; D003131:Combined Modality Therapy; D019337:Hematologic Neoplasms / Q000150:complications* / Q000401:mortality / Q000503:physiopathology; D006439:Hemodynamics; D006801:Humans; D008020:Life Support Care; D009102:Multiple Organ Failure / Q000175:diagnosis / Q000209:etiology* / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D010100:Oxygen / Q000097:blood; D012772:Shock, Septic / Q000150:complications* / Q000175:diagnosis / Q000209:etiology / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D018709:Statistics, Nonparametric
chemical_list: D010100:Oxygen